Advance market commitments for paediatric and rare cancer drugs
Payers would promise in advance to buy a set number of doses at a set price for any drug that meets a defined bar in a rare or childhood cancer, so companies know the market exists before they invest.
Modelled on Gavi's pneumococcal advance market commitment, a consortium of national payers and foundations pledges a guaranteed purchase (volume times price, for example $300 million over ten years) for the first therapy meeting a target product profile in a specified rare or paediatric indication: diffuse midline glioma, relapsed neuroblastoma, Ewing sarcoma, rare fusion-driven cancers. In exchange, the developer accepts a long-run affordable price and supply commitments. The commitment is only paid on delivery of a product that meets pre-registered efficacy criteria, so payers bear no risk of failure.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
Pages like this
not linked directly; found by shared links- IdeaAn international consortium pooling the outcome of every treated child with cancer
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaPay a prize for rare cancer drugs instead of hoping for a market
Shares Neuroblastoma (paediatric), Incentives reward me-too drugs and marginal gains, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaMake paediatric combination studies part of every relevant adult cancer drug approval
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- InstitutionChildren's Cancer Hospital Egypt 57357
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Sarcomas (soft tissue, bone, GIST), Glioma & glioblastoma.
- IdeaPatent-free open-source development of repurposed and off-patent cancer drugs
Shares A non-profit pharmaceutical company for the cancers markets ignore, Incentives reward me-too drugs and marginal gains, Sarcomas (soft tissue, bone, GIST).
- InstitutionChildren's Cancer and Leukaemia Group
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Sarcomas (soft tissue, bone, GIST), Glioma & glioblastoma.
- InstitutionSydney Children's Hospitals Network / Children's Cancer Institute
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Sarcomas (soft tissue, bone, GIST), Glioma & glioblastoma.
- InstitutionSIOP Europe – European Society for Paediatric Oncology
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).